AbbVie (prior sponsor, Abbott)
Quick facts
Phase 3 pipeline
- ABT-267 · Immunology / Inflammation
ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation. - ABT-333 · Virology / Hepatology
ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication. - ABT-450/r/ABT-267, ABT-333 · Virology / Hepatology
This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes. - ABT-450/ritonavir · Virology / Hepatology
ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels. - ABT-712 · Oncology
ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation. - Leuprolide Acetate 3 Month Depot · Oncology; Endocrinology
Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production. - Open-label Adalimumab · Immunology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - Placebo for ABT-333
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. - Placebo for ABT-450/r/ABT-267 · Hepatology
This is a placebo control with no active pharmacological mechanism. - Placebo (PBO) oral capsules
Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.
Phase 2 pipeline
- ABT-288 High Dose · Diabetes
ABT-288 High Dose is a glucagon receptor antagonist. - ABT-288 Low Dose
- ABT-450 · Infectious Diseases
ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus. - ABT-652 · Immunology / Respiratory
ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. - ABT-652 NSAID
- ABT-806
- ABT-888 · Oncology
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes. - ABT-894 · Multiple Sclerosis, Autoimmune Diseases
ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). - ABT-981
- Adalimumab, current formulation · Immunology
Tumor necrosis factor-alpha inhibitor - Adalimumab, new formulation · Immunology
Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine. - Atrasentan high dose group · Cardiovascular
Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. - Atrasentan low dose group · Cardiovascular
Endothelin receptor antagonist - New formulation adalimumab
Phase 1 pipeline
- ABT-348
- ABT-348 and azacitidine · Oncology
AZA is a hypomethylating agent that targets DNA methyltransferase enzymes. - ABT-348 and carboplatin
- ABT-348 and docetaxel · Oncology
Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division. - ABT-700
- ABT-767
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- AbbVie (prior sponsor, Abbott) portfolio CI brief
- AbbVie (prior sponsor, Abbott) pipeline updates RSS
Frequently asked questions about AbbVie (prior sponsor, Abbott)
What is AbbVie (prior sponsor, Abbott)'s pipeline?
AbbVie (prior sponsor, Abbott) has 10 drugs in Phase 3, 14 in Phase 2, 6 in Phase 1. Late-stage candidates include ABT-267, ABT-333, ABT-450/r/ABT-267, ABT-333, ABT-450/ritonavir.
Related
- Sector hub: All tracked pharma companies